×
Taysha Gene Therapies Price to Free Cash Flow Ratio 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Taysha Gene Therapies price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
View More
Taysha Gene Therapies Price to Free Cash Flow Ratio 2020-2024 | TSHA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
PE Ratio
P/S Ratio
Price/Book Ratio
Price-FCF Ratio
Net Worth
Taysha Gene Therapies price to free cash flow ratio from 2020 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company Name
Market
Cap
Teva Pharmaceutical Industries (TEVA)
$19B
Dr Reddy's Laboratories (RDY)
$12B
BridgeBio Pharma (BBIO)
$4.3B
Bausch Health Cos (BHC)
$3B
Amphastar Pharmaceuticals (AMPH)
$2.1B
Supernus Pharmaceuticals (SUPN)
$2B
Personalis (PSNL)
$261M
Assembly Biosciences (ASMB)
$98M
Sol-Gel Technologies (SLGL)
$12M
Evoke Pharma (EVOK)
$7M
Teligent (TLGT)
$0M